Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Roberta Caputo
Observed names:
Caputo, Roberta,
R. Caputo,
Roberta, Caputo
Institutions:
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale",
Istituti di Ricovero e Cura a Carattere Scientifico,
Fondazione IRCCS Istituto Nazionale dei Tumori
Observed institutions:
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale",
Istituti di Ricovero e Cura a Carattere Scientifico,
Fondazione IRCCS Istituto Nazionale dei Tumori,
University of Naples Federico II
ORCID:
0000-0003-4231-1184
Observed ORCID:
0000-0003-4231-1184
OpenAlex ID:
A5110249663
Antitumor Activity of ZD6474, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Human Cancer Cells with Acquired Resistance to Antiepidermal Growth Factor Receptor Therapy
2004
·
Fortunato Ciardiello
, Roberto Bianco
, et al.
·
Clinical Cancer Research
·
359
Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase.
2003
·
Fortunato Ciardiello
, Rosa Caputo
, et al.
·
PubMed
·
352
Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa).
2002
·
Cataldo Bianco
, Giampaolo Tortora
, et al.
·
PubMed
·
264
Targeting Cell Cycle in Breast Cancer: CDK4/6 Inhibitors
2020
·
Michela Piezzo
, Stefania Cocco
, et al.
·
International Journal of Molecular Sciences
·
231
PDF
Inhibition of autophagy by chloroquine prevents resistance to PI3K/AKT inhibitors and potentiates their antitumor effect in combination with paclitaxel in triple negative breast cancer models
2022
·
Stefania Cocco
, Alessandra Leone
, et al.
·
Journal of Translational Medicine
·
138
PDF
Biomarkers in Triple-Negative Breast Cancer: State-of-the-Art and Future Perspectives
2020
·
Stefania Cocco
, Michela Piezzo
, et al.
·
International Journal of Molecular Sciences
·
137
PDF
Toxicity profile of antibody-drug conjugates in breast cancer: practical considerations
2023
·
Andrea D’Arienzo
, Annarita Verrazzo
, et al.
·
EClinicalMedicine
·
126
PDF
Targeting Autophagy in Breast Cancer
2020
·
Stefania Cocco
, Alessandra Leone
, et al.
·
International Journal of Molecular Sciences
·
121
PDF
Progression-Free Survival and Overall Survival of CDK 4/6 Inhibitors Plus Endocrine Therapy in Metastatic Breast Cancer: A Systematic Review and Meta-Analysis
2020
·
Michela Piezzo
, Paolo Chiodini
, et al.
·
International Journal of Molecular Sciences
·
119
PDF
Sacituzumab Govitecan for the treatment of advanced triple negative breast cancer patients: a multi-center real-world analysis
2024
·
Roberta Caputo
, Giuseppe Buono
, et al.
·
Frontiers in Oncology
·
93
PDF
T-DM1 and brain metastases: Clinical outcome in HER2-positive metastatic breast cancer
2018
·
Alessandra Fabi
, Daniele Alesini
, et al.
·
The Breast
·
62
Combined targeted inhibition of bcl-2, bcl-XL, epidermal growth factor receptor, and protein kinase A type I causes potent antitumor, apoptotic, and antiangiogenic activity.
2003
·
Giampaolo Tortora
, Rosa Caputo
, et al.
·
PubMed
·
59
Real-World Outcomes of Trastuzumab Deruxtecan in Patients With HER2+ Metastatic Breast Cancer: The DE-REAL Study
2023
·
Andrea Botticelli
, Roberta Caputo
, et al.
·
The Oncologist
·
52
PDF
Combined Targeting of Epidermal Growth Factor Receptor and MDM2 by Gefitinib and Antisense MDM2 Cooperatively Inhibit Hormone-Independent Prostate Cancer
2004
·
Roberto Bianco
, Roberta Caputo
, et al.
·
Clinical Cancer Research
·
50
PDF
Human epidermal growth factor receptor 2 dual blockade with trastuzumab and pertuzumab in real life: Italian clinical practice versus the CLEOPATRA trial results
2018
·
Sabino De Placido
, Mario Giuliano
, et al.
·
The Breast
·
37
Serum thymidine kinase activity in patients with HR-positive/HER2-negative advanced breast cancer treated with ribociclib plus letrozole: Results from the prospective BioItaLEE trial
2023
·
Luca Malorni
, Giampaolo Bianchini
, et al.
·
European Journal of Cancer
·
35
PDF
Prognostic and clinical impact of the endocrine resistance/sensitivity classification according to international consensus guidelines for advanced breast cancer: an individual patient-level analysis from the Mammella InterGruppo (MIG) and Gruppo Italiano Mammella (GIM) studies
2023
·
Matteo Lambertini
, Eva Blondeaux
, et al.
·
EClinicalMedicine
·
33
PDF
CAR-T cell therapy for breast cancer: Current status and future perspective
2024
·
Giuseppe Buono
, Monica Capozzi
, et al.
·
Cancer Treatment Reviews
·
31
Central obesity, body mass index, metabolic syndrome and mortality in Mediterranean breast cancer patients
2023
·
Anna Crispo
, Livia S. A. Augustin
, et al.
·
Scientific Reports
·
26
PDF
Survival Following CDK4/6 Inhibitor Therapy for Hormone Receptor–Positive, ERBB2–Negative Metastatic Breast Cancer
2025
·
Pier Paolo Maria Berton Giachetti
, Stefania Morganti
, et al.
·
JAMA Network Open
·
22
PDF
Factors associated with first-to-second-line attrition among patients with metastatic breast cancer in the real world
2025
·
E. Blondeaux
, L. Boni
, et al.
·
ESMO Open
·
21
Real life outcome analysis of breast cancer brain metastases treated with Trastuzumab Deruxtecan
2025
·
Alessandra Fabi
, Alessandro Rossi
, et al.
·
npj Precision Oncology
·
17
PDF
Gene Expression Assay in the Management of Early Breast Cancer
2019
·
Roberta Caputo
, Daniela Cianniello
, et al.
·
Current Medicinal Chemistry
·
16
Prognostic implications of risk definitions from the monarchE and NATALEE trials
2025
·
Luca Arecco
, Eva Blondeaux
, et al.
·
JNCI Journal of the National Cancer Institute
·
15
PDF
Eribulin for metastatic breast cancer (MBC) treatment: a retrospective, multicenter study based in Campania, south Italy (Eri-001 trial)
2017
·
Michele Orditura
, Adriano Gravina
, et al.
·
ESMO Open
·
15
Show more works
View as search
Works count:
91
Citation count:
2,583
H-index:
21
I10-index:
30
Year
Topic
Type